Previous 10 | Next 10 |
2023-12-04 16:26:58 ET More on EyePoint Pharmaceuticals Shorting EyePoint Pharmaceuticals Ahead Of Davio-2 Wet-AMD Data: Potential 78% Gain Countdown To Clarity: EyePoint's December Data Delivery EyePoint Pharmaceuticals, Inc. (EYPT) Q3 2023 Earnings Conference Call ...
2023-12-04 12:47:12 ET Gainers: Hawaiian Holdings ( HA ) +187% . EyePoint Pharmaceuticals ( EYPT ) +177% . SilverSun Technologies ( SSNT ) +176% . Alterity Therapeutics Ltd ( ATHE ) +122% . View ( VIEW ) +82% . enGene Holding...
2023-12-04 12:22:42 ET DENVER, Colo., Dec. 4, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; SilverSun Technologies Inc (NASDAQ: SSNT), EyePoint Pharmaceuticals Inc (NASDAQ: EYPT), Alterity Therap...
2023-12-04 10:02:05 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble For further details see: Ocular Therapeutix, EyePoint Pharmaceuticals among healthcare movers
2023-12-04 10:01:55 ET DENVER, Colo., Dec. 4, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; EyePoint Pharmaceuticals Inc (NASDAQ: EYPT), SilverSun Technologies Inc (NASDAQ: SSNT), Alterity Therapeutics ...
2023-12-04 08:26:05 ET More on EyePoint Pharma Shorting EyePoint Pharmaceuticals Ahead Of Davio-2 Wet-AMD Data: Potential 78% Gain Countdown To Clarity: EyePoint's December Data Delivery EyePoint Pharmaceuticals, Inc. (EYPT) Q3 2023 Earnings Conference Call Transcrip...
– Both EYP-1901 cohorts demonstrated a statistically non-inferior change in BCVA versus aflibercept control with a numerical difference of only -0.3 and -0.4 letters, respectively for the 2 mg and 3 mg dose at blended six-month endpoint – – Positive safety p...
2023-11-30 16:39:16 ET Summary EyePoint Pharmaceuticals, Inc. is expected to release Phase 2 data for its product candidate EYP-1901 in treating wet-AMD in December. The Phase 2 data suggests that the study may fail, with a difference in BCVA between EYP-1901 and control Eylea of ...
2023-11-24 13:00:31 ET More on the markets Broad Turn In Weekly Momentum Bodes Well For Stocks SPY: When Indicators Speak, The Year-End Rally Makes Little Sense 2024 U.S. Equities Outlook: Expect Bulls To Win This Round, Too Best stocks for when the 10-year T...
2023-11-08 08:04:15 ET Summary EYP-1901 shows potential in wet AMD, underpinned by EyePoint's financial stability and innovative Durasert technology. Despite a decrease in product sales, increased R&D spend and a stable cash position suggest a robust pipeline focus. The DA...
News, Short Squeeze, Breakout and More Instantly...
EyePoint Pharmaceuticals Inc. Company Name:
EYPT Stock Symbol:
NASDAQ Market:
EyePoint Pharmaceuticals Inc. Website:
– Two New Independent Directors, Stuart Duty and Andrew Saik, Appointed – Third New Independent Director to Be Appointed to Board in Near Term MONTREAL and CHARLOTTE, N.C., July 15, 2024 (GLOBE NEWSWIRE) -- Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) (...
– Phase 3 trial design for the LUGANO and LUCIA pivotal non-inferiority trials of DURAVYU in wet AMD based on positive EOP2 meeting with FDA; on track for trial initiation in 2H 2024 – – Positive twelve-month safety and efficacy data from Phase 2 DAVIO 2 clinical tria...
WATERTOWN, Mass., June 18, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company will host an R...